Delivery Order SPE2DB20D2104-SPE2DB24FS49W
- Not listed
- The Defense Logistics Agency (DLA) has awarded a firm fixed price delivery order contract to Amerisourcebergen Drug Corp, a subsidiary of Amerisourcebergen Corporation, a global pharmaceutical sourcing and distribution company. The contract, valued at $9,698.52, is for the delivery of Multaq 400 mg tablets. This award is part of a larger indefinite delivery contract (IDC) with a potential value of $999,999,999.00 that Amerisourcebergen Drug Corp holds with DLA, which serves as the primary...
- This federal contract award issued by the Defense Logistics Agency (DLA) to Amerisourcebergen Drug Corp, a subsidiary of Amerisourcebergen Corporation, is for the delivery of Multaq 400 mg tablets. The $4,120.50 firm fixed-price delivery order has a completion date of June 12, 2024. Amerisourcebergen holds a significant $999,999,999.00 Indefinite Delivery Contract (IDC) with the DLA Troop Support Medical to provide a comprehensive range of pharmaceutical products and medical supplies,...
- This is a federal contract award to Amerisourcebergen Drug Corp, a major pharmaceutical distributor and healthcare solutions provider, by the Defense Logistics Agency (DLA) Troop Support Medical. The contract, valued at $1,785.46, is a Delivery Order for Multaq 400 mg Tablets. The contract has no set-aside designation, indicating open competition. Amerisourcebergen holds a significant $999,999,999 Indefinite Delivery Contract (IDC) with the DLA Troop Support Medical, which serves as a primary...
- This federal contract award was issued by the Defense Logistics Agency (DLA) to Amerisourcebergen Drug Corporation, a major pharmaceutical distributor and healthcare solutions provider. The $21,298.99 firm-fixed-price delivery order is for the supply of Multaq 400 mg tablets. The contract has a period of performance through May 9, 2025 and is not set aside. Amerisourcebergen holds a significant $999,999,999.00 Indefinite Delivery Contract (IDC) with the DLA Troop Support Medical, which...
- The Defense Logistics Agency (DLA) awarded a firm fixed price delivery order to AmerisourceBergen Drug Corp, a subsidiary of AmerisourceBergen Corporation, to supply Multaq 400 mg tablets. The $26,758.04 delivery order was placed under an existing $999,999,999.00 indefinite delivery contract (IDC) held by AmerisourceBergen Drug Corp to provide a comprehensive range of pharmaceutical products and medical supplies to DLA Troop Support Medical facilities supporting the Department of Defense. This...
- This federal contract award from the Defense Logistics Agency (DLA) is a delivery order valued at $13,093.98 to Amerisourcebergen Drug Corp, a major pharmaceutical distributor and healthcare solutions provider. The contract is for the supply of MULTAQ 400 MG TABLET 60S, with a completion date of July 26, 2024. Amerisourcebergen holds a $999,999,999 Indefinite Delivery Contract (IDC) with the DLA Troop Support Medical, which serves as a primary vehicle for providing a comprehensive range of...
- The Defense Logistics Agency (DLA) has awarded a firm fixed price delivery order contract valued at $4,197.60 to Amerisourcebergen Drug Corp, a subsidiary of Amerisourcebergen Corporation, a leading global pharmaceutical sourcing and distribution services company. The contract is for the provision of MULTAQ 400 MG TABLET 60S, a specialty pharmaceutical product. This delivery order award is under a larger indefinite delivery contract (IDC) between DLA and Amerisourcebergen Drug Corp, with a...
- This federal contract award was made by the Defense Logistics Agency (DLA) to AmerisourceBergen Drug Corp, a major pharmaceutical distributor and healthcare solutions provider. The contract, valued at $6,297.44, is for the delivery of Multaq 400 mg tablets. It is a firm fixed-price delivery order contract with a period of performance through July 9, 2024. The contract does not have a set-aside designation, indicating open competition. AmerisourceBergen holds a significant $999,999,999 Indefinite...
- This federal contract award, valued at $8,354.02, was issued by the Defense Logistics Agency (DLA) to Amerisourcebergen Drug Corp, a major pharmaceutical distributor. The award is a delivery order contract for the supply of Multaq 400 mg tablets. The contract is a firm fixed-price, non-set-aside award with a performance period ending on April 23, 2025. Amerisourcebergen Drug Corp holds a substantial Indefinite Delivery Contract (IDC) with the DLA Troop Support Medical, valued at $999,999,999.00,...
- The U.S. Defense Logistics Agency (DLA) Troop Support Medical awarded a $9,238.27 firm-fixed-price delivery order to Amerisourcebergen Drug Corp's Corporate Office Division. The contract is to provide 4565456832 MULTAQ 400 MG TABLET 60S, with a performance period through August 15, 2024. This award is part of a larger Indefinite Delivery Contract (IDC) valued at up to $999,999,999 that Amerisourcebergen holds with DLA Troop Support Medical for a broad range of pharmaceutical and medical supplies...
- SPE2DB20D2104Indefinite Delivery Contract
- SPE2DB20D2104-SPE2DB24FS49WDelivery Order
The Defense Logistics Agency (DLA) awarded a delivery order contract worth $1,430.70 to Amerisourcebergen Drug Corp, a major pharmaceutical distributor, for the supply of Multaq 400 mg tablets. This delivery order is part of a larger Indefinite Delivery Contract (IDC) valued at up to $999,999,999.00 that Amerisourcebergen Drug Corp holds with the DLA Troop Support Medical. The IDC, which runs through November 2026, enables the DLA to efficiently procure a comprehensive range of pharmaceutical products and medical supplies, including specialty medications, brand-name and generic drugs, vaccines, syringes, and other critical medical commodities to support military healthcare programs globally. The contract award does not have a set-aside designation, indicating open competition. Amerisourcebergen Drug Corp is a subsidiary of the parent company, Cencora, Inc., which also holds a separate IDC with the Department of Justice Federal Bureau of Investigation valued at up to $750,000 through May 2024 for similar medical products and prescription drugs.
Mod # | Description | ReasonForModification | Federal Obligation | Date |
|---|---|---|---|---|
| Not listed | Not listed | $1.4k | 2/9/24 |